Stanley D. Stearns and James A. Ramin' v. Beckman Instruments, Inc.Stanley D. Stearns and James A. Ramin' v. Beckman Instruments, Inc.
In this patent infringement case, the court substitutes the following opinion for publication in place of its previous unpublished opinion, without any change in its holding or in the reasoning utilized. Appellants Stearns and Ramin’ (Steаrns) appeal from a judgment of the United States District Court for the Southern District of Texas, holding U.S. patent No. 4,022,065, issued to Ramin’ and Stearns (the Ramin’ patent), invalid under
Background
The Ramin’ patent relates to an improvement in high pressure liquid chromatography equipment used for qualitative and quantitative analysis of a liquid chemical sample. Liquid chromatography involves separating the components of a liquid sample by measuring the differences in their rates of absorption by a stationary material from a moving stream of liquid. The invention is a sample injection syringe for introducing small volumes of sample into the chromatograph allowing accurate measurement and delivery of small samples. The calibrations on the syringe are offset by the connecting volume of sample held in the chromatograph betweеn the syringe outlet and the front end of the sample to be injected. Thus, the syringe automatically overinjects into the valve an amount of sample precisely equal to the dead volume of sample that remains in the valve.
Ramin’ was formerly the major shareholder, president, and chief executive officer of Glenco Scientific, Inc. (Glenco). Stearns was and is the controlling shareholder and chief executive officer of Valeo Instruments Co., Inc. (Valeo). The district court found that, prior to October 29, 1974, Valeo was manufacturing and selling, in part through Glenco, a line of high pressure and ultra-high pressure sample injection valves in competition with Beckman. Further, the court found that on October 29, 1974, Stearns of Valeo and Ramin’ of Glenco discussed, by telephone, making a special syringe sample injection apрaratus. As a result of that conversation, Glenco made the first prototype of the invention. The needle of the “first prototype,” however, was too slender and, on November 16, 1974, Ramin’ ordered the production by Glenco of a “second prototype” having a thicker needle and the claimed offset calibration scale.
The court found that one of these “second prototype” syringes was sеnt to Dr. Richard Henry of Spectra-Physics for the purpose of inducing Spectra-Physics to purchase the syringe from Glenco. The purpose of that submission was found to be commercial and not experimental.
Ramin’ conversed with Dr. Silvestre Te-jada of the United States Environmental Protection Agency (EPA) regarding the sample injection syringe and quoted Dr. Tejada a price of $48 for each syringe. Subsequently, two EPA proсurement requests were prepared and, on February 4, 1975, Glenco received a telephone order for the syringes from EPA. On February 21, 1975, Glenco shipped to Dr. Tejada two of the “second prototype” syringes which were received on or about February 28, 1975.
In March 1975, Stearns and Ramin’ attended the “Pittsburgh Conference” at which they demonstrated, and distributed literature describing, their syringe. Several sales were generated by these demonstrations.
Ramin’ and Stearns, on February 19, 1976, filed application No. 659,373, the successful prosecution of which resulted in the issuance of thе Ramin’ patent on May 10, 1977. They then filed suit against Beck-man in the United States District Court for the Southern District of Texas alleging infringement of the Ramin’ patent. The district court entered summary judgment in favor of Beckman holding the Ramin’ patent invalid as “on sale” under
On remand, the district court once again held the Ramin’ patent invalid under
Issues
Five principal questions are presented by this appeal:
(1) whether the district court erred in adjudicating the validity of all claims of the Ramin’ patent where infringement of only claims 8 and 9 was placed in issue by the parties;
(2) whether the trial judge has an obligation underFed.R.Civ.P.41(b) to weigh the evidence or, rather, whether a rule 41(b) motion is evaluated by the trial court under the directed verdict stаndard;
(3) whether the district court erred in concluding that the invention claimed in the Ramin’ patent was “on sale” within the meaning of35 U.S.C. § 102(b) ;
(4) whether the district court erred in concluding that the claims of the Ra-min’ patent would have been obvious under35 U.S.C. § 103 ; and
(5) whether the trial court’s failure to find infringement of claims 8 and 9 of the Ramin’ patent is clearly erroneous.
Claims in Issue
The court below held that the Ra-min’ patent is invalid, yet, only claims 8 and 9 of the Ramin’ patent wеre in issue. Beckman did not seek a declaratory judgment of invalidity of any of the claims of the Ramin’ patent.
3
Consequently, when appellants Stearns and Ramin’ amended their complaint prior to trial to chаrge infringement of only claims 8 and 9, claims 1-7 and 10 were removed from consideration. While the pretrial stipulation may direct the evidence to be offered, it is ineffective to grant to the district court the pоwer to decide an issue not properly before it for decision. Thus, the judgment of invalidity of claims 1-7 and 10 of the Ra-min’ patent is vacated.
4
Preservation of claims 1-7 and 10 under
Standard of Proof Under
Judgment was entered against Stearns under
Prior to the 1946 amendment of
The district court applied the correct standard, entered appropriate findings of fact, and properly entered judgment on the merits under rule 41(b). Even assuming Stearns had established a prima facie case on the merits, that would not preclude entry of judgment under
Law of the Case
Relying on the opinion of the Fifth Circuit reversing the trial court’s earlier grant of summary judgment in this case, Stearns contends that the law of the case doctrine precluded the district court from finding the Ramin’ patent invalid as “on sale” under
“On Sale” Bar
The district court evaluated the conflicting testimony and evidence and found that the claimed invention was reduced to practice in December 1974 by virtue of the “second prototype.” Further, it found that the problems associated with the “second prototype” would not affect its suitability for quantitative analysis. Thus, the district court construed the claims in accord-
Although we have some problems with the reasoning of the court below in its approach to the issue of validity under
■ Costs on Appeal
We turn now to Beckman’s request for expenses resulting from this appeal. Beckman contends that Steаrns’ appeal is frivolous. We disagree. Stearns has prevailed on the argument that claims 1-7 and 10 were not before the trial court for decision. Further, Stearns’ argument that
AFFIRMED IN PART, VACATED IN PART.
Notes
.
Stearns v. Beckman Instruments, Inc.,
.
Stearns v. Beckman Instruments, Inc.,
.
Felburn v. New York Cent. R.R.,
.
Connell v. Sears, Roebuck
&
Co.,
.
Back v. Friden Calculating Mach. Co.,
. 5 MOORE’S FEDERAL PRACTICE ¶ 41.13[4];
Schad v. Twentieth Century-Fox Film Corp.,
. 5 MOORE'S FEDERAL PRACTICE ¶ 41.13[7],
.
Weissinger v. United States,
. IB J. MOORE, J. LUCAS, T. CURRIER, MOORE’S FEDERAL PRACTICE ¶ 0.404[l] (2d ed. 1983).